cefepime-zidebactam
Selected indexed studies
- New β-Lactam-β-Lactamase Inhibitor Combinations. (Clin Microbiol Rev, 2020) [PMID:33177185]
- Cefepime-zidebactam therapy for extensively drug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae infection as a bridge to liver transplantation. (JAC Antimicrob Resist, 2025) [PMID:40678583]
- β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. (Pathogens, 2025) [PMID:40005543]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- New β-Lactam-β-Lactamase Inhibitor Combinations. (2020) pubmed
- Cefepime-zidebactam therapy for extensively drug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae infection as a bridge to liver transplantation. (2025) pubmed
- β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. (2025) pubmed
- Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. (2021) pubmed
- In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. (2023) pubmed
- In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. (2017) pubmed
- Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. (2022) pubmed
- Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres. (2019) pubmed
- Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution. (2022) pubmed
- Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2. (2025) pubmed